On November 8, 2018 Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics), reported that Ton Logtenberg, Ph.D., President and Chief Executive Officer of Merus, will present a company overview at the Jefferies 2018 London Healthcare Conference on Thursday, November 15, 2018, at 3:20 p.m. GMT (Press release, Merus, NOV 8, 2018, View Source;p=RssLanding&cat=news&id=2376165 [SID1234532116]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors and Media page of the Company’s website, View Source A replay of the presentation will be archived and available on the Merus website site for a limited time following the event.